These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24184249)

  • 1. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
    Matsumoto Y; Mori Y; Kageyama S; Arihara K; Sugiyama T; Ohmura H; Yakushigawa T; Sugiyama H; Shimada Y; Nojima Y; Shio N
    J Am Coll Cardiol; 2014 Feb; 63(6):528-36. PubMed ID: 24184249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone in chronic hemodialysis patients improves cardiac function.
    Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.
    Lin C; Zhang Q; Zhang H; Lin A
    J Clin Hypertens (Greenwich); 2016 Feb; 18(2):121-8. PubMed ID: 26224543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
    Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
    Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
    Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
    Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the month. The RALES study (randomized aldactone evaluation study].
    Kulbertus H
    Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.
    Pitt B; Rossignol P
    J Am Coll Cardiol; 2014 Feb; 63(6):537-8. PubMed ID: 24184253
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
    Baker WL; White WB
    Ann Pharmacother; 2012 Jun; 46(6):889-94. PubMed ID: 22669801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients.
    Michea L; Vukusich A; González M; Zehnder C; Marusic ET
    Kidney Int; 2004 Oct; 66(4):1647-53. PubMed ID: 15458462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.